Physician profile
Scott A Gordon
NPI 1033140801
$7,975.81
in general payments reported to CMS, 2019-2025
50 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $647 · 2021: $1,396 · 2022: $1,218 · 2023: $1,503 · 2024: $1,390 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,092.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $873.14 | 2019-2025 | Benlysta, Shingrix |
| Astellas Pharma US INC | $687.89 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $550.34 | 2019-2025 | |
| Lilly USA, LLC | $491.46 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $321.77 | 2020-2025 | Evenity, Prolia |
| Novo Nordisk INC | $321.38 | 2019-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $265.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.97 | 2020-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $242.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $229.84 | 2019-2021 | |
| Abbvie INC. | $219.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $206.38 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $197.45 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $192.70 | 2021-2025 | Farxiga, Airsupra |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.